The Pharma Data

AUGUST 20, 2020

The drugmakers lost out to domestic producers, which in some cases undercut prices for established medicines by more than 90%, according to Jiemian. Among the drugs to lose contracts were Eli Lilly schizophrenia medicine Zyprexa and Pfizer’s Viagra, the publication said. Virtual Event. DEVELOP A UNIFIED SCIENTIFIC VOICE.

Research Analyst 52

Research Analyst Medicine Pharma Companies Marketing 52

Roots Analysis

JANUARY 23, 2024

The peptide therapeutics market has undergone substantial evolution since the inception of insulin. Presently, over 80 peptide-based drugs are available in the market for myriad of disorders and diseases. Presently, over 80 peptide-based drugs are available in the market for myriad of disorders and diseases.

Development 40

Development Contract Manufacturing Drugs Manufacturing 40

The Pharma Data

DECEMBER 31, 2020

Prior to that, Zhang was an equity research analyst at UBS in New York, where he covered the Major and Specialty Pharmaceutical Sector. a publicly-listed company investing in blockchain technology solutions for capital markets and other sectors that can benefit from tokenization. He is currently the CEO of BlockchainK2 Corp.,

Gene Therapy 52

Gene Therapy Engineer Gene Research Analyst 52

The Pharma Data

DECEMBER 28, 2020

Zhang was an equity research analyst at UBS in New York , where he covered the Major and Specialty Pharmaceutical Sector. in its healthcare practice and conducted postdoctoral research in diabetes-related drug development at Boston University’s School of Medicine.

Clinical Trials 40

Clinical Trials Clinical Trials Research Analyst Trials 40

Roots Analysis

FEBRUARY 23, 2024

This helps to speed up the process of making new medicines and finding cures for diseases. With the rising demand for antibody therapeutics in the recent past, the domain of antibody discovery has seen a significant market growth towards outsourcing.

Antibody 40

Antibody Research Marketing Scientist 40

Pharmaceutical Technology

JANUARY 27, 2023

In 2019, Cablivi became the first FDA-approved , nanobody-based medicine for acquired thrombotic thrombocytopenic purpura (aTTP), an ultra-orphan condition that causes blood clots in small blood vessels around the body. The disorder has a reported annual incidence between 1.5 cases per million in Europe.

Manufacturing 130

Manufacturing Drugs Research Analyst FDA Approval 130